An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932893 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

347

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: PF-02341066
DRUG: Pemetrexed
DRUG: Docetaxel

Sponsor

Pfizer